# Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS

> **NCT02265666** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BIIL 284 BS Tablet FF
- **DRUG:** BIIL 284 BS tablet C
- **OTHER:** standard breakfast

## Key facts

- **NCT ID:** NCT02265666
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2001-11
- **Final completion:** —
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02265666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02265666, "Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02265666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*